Drilldown: Medicines
Use the filters below to narrow your results.
generic:
25B-NBOH (1) ·
25B-NBOMe (1) ·
25C-NBOH (1) ·
25C-NBOMe (1) ·
25I-NBOH (1) ·
25I-NBOMe (1) ·
25N-NBOMe (1) ·
2C-B (1) ·
2C-B-FLY (1) ·
2C-C (1) ·
2C-D (1) ·
2C-E (1) ·
2C-I (1) ·
2C-P (1) ·
2C-T-2 (1) ·
2C-T-7 (1) ·
Allylescaline (1) ·
Azelastine (1) ·
Bromo-DragonFLY (1) ·
DOB (1) ·
DOC (1) ·
DOI (1) ·
DOM (1) ·
Escaline (1) ·
Ketotifen (1) ·
Methallylescaline (1) ·
Olopatadine (1) ·
Proscaline (1) ·
TMA-2 (1)
brand:
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (12) ·
5-HT2A agonist; long duration (1) ·
5-HT2A agonist; MAO inhibitor (1) ·
5-HT2A agonist; milder than other 2C-x (1) ·
5-HT2A partial agonist (1) ·
Extremely potent 5-HT2A agonist; vasoconstrictor (1) ·
Extremely potent 5-HT2A agonist; very long duration (1) ·
Potent 5-HT2A agonist (5) ·
Potent 5-HT2A agonist; no oral activity (1) ·
Potent 5-HT2A agonist; very long duration (1) ·
Very potent 5-HT2A agonist; long duration (1) ·
'"`UNIQ--vote-000011D5-QINU`"' Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients'"`UNIQ--ref-000011D6-QINU`"'. (1) ·
'"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1) ·
'"`UNIQ--vote-000013B1-QINU`"' Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue'"`UNIQ--ref-000013B2-QINU`"'. (1)
uses:
starting dose:
None (26) ·
Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID (1) ·
Ophthalmic 1 drop in each eye every 8-12 hours (1) ·
Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID (1)
preparations:
None (26) ·
0.025%, 0.035% ophthalmic solutions (1) ·
0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray (1) ·
0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray) (1)
fda max:
routes:
onset:
duration:
halflife:
None (25) ·
Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) ·
Not well characterized (1) ·
~22 hours; longer 54 hours (desmethylazelastine, active metabolite)'"`UNIQ--ref-000013B6-QINU`"' (1) ·
~3 hours (systemic, when measurable; topical action dominates)'"`UNIQ--ref-000011D9-QINU`"' (1)
bioavailability:
pregnancy:
None (25) ·
Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; second-line to intranasal corticosteroids or PO loratadine/cetirizine.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not established (1)
legal:
None (25) ·
OTC (Astepro 0.15%) and [[USLegal:Prescription only|Rx-only]] (other intranasal, ophthalmic, Dymista) in US (1) ·
OTC (Pataday ophthalmic) and [[USLegal:Prescription only|Rx-only]] (Patanase intranasal) in US (1) ·
OTC in US (1) ·
[[USLegal:DEA Schedule I|Schedule I]] (United States) (1)
Showing below up to 29 results in range #1 to #29.